Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06604858 2026-04-07

TELESCOPE

Phase 2 Active not recruiting

31 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05181462 2026-04-06

TRIFOUR

Phase 1/2 Active not recruiting

117 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05382299 2026-04-06

ASCENT-03

Phase 3 Active not recruiting

623 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04877821 2026-04-02

NeoSACT

Phase 2 Completed

29 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07017673 2026-04-02

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Phase 2 Recruiting

34 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02445391 2026-04-01

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Phase 3 Active not recruiting

415 enrolled 15 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06926868 2026-04-01

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

500 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01525966 2026-03-30

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 12 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07394387 2026-03-19

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Phase 2 Recruiting

39 enrolled

Breast

Triple Negative Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06318897 2026-03-04

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Phase 2 Recruiting

28 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04191135 2026-03-03

KEYLYNK-009

Phase 2 Completed

462 enrolled 30 charts

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2 Active not recruiting

83 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06802757 2026-02-25

PRISM-TNBC

Phase 2 Recruiting

72 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

Phase 2 Recruiting

85 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07413601 2026-02-17

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

Phase 2 Not yet recruiting

78 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Phase 2 Completed

29 enrolled 15 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Phase 1 Not yet recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07283692 2026-02-03

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Phase 2 Not yet recruiting

46 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06279364 2026-01-27

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 3 Recruiting

524 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

SASCIA

ToPCourT

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

TroFuse-011

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

RAINFOL-01

TELESCOPE

TRIFOUR

ASCENT-03

NeoSACT

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

I-SPY

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

KEYLYNK-009

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

PRISM-TNBC

MK-5890-003

TARMAC

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer